• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Human Genome Sciences

Human Genome Sciences

  1. All
  2. Morningstar Articles
  3. Investing
  4. Research
  1. Managing Expectations, Part II

    On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...

  2. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  3. Health-Care Investing Alive and Well

    Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.

  4. The Market's Most Overvalued Stocks

    Equity valuations as a whole have barely budged in 2005, but the market remains a bit on the pricey side when comparing to Morningstar's collective fair value estimates (To see more on Morningstar's perspective on market valuations, check out our Market Valuation Graph ). The median stock in our ...

  5. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

  6. Is It Time for the Fed to ‘Level’ With Markets?

    Human Genome Sciences' two big drugs could make up for years of losses.

©2017 Morningstar Advisor. All right reserved.